Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Early research (Phase 1)Study completedNCT02437370
What this trial is testing

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Who this might be right for
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and Ureter+6 more
University of California, Davis 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04940299
What this trial is testing

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Bladder Carcinoma+39 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Study completedNCT02459119
What this trial is testing

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

Who this might be right for
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
University of Alabama at Birmingham 17
Large-scale testing (Phase 3)Active Not RecruitingNCT03682068
What this trial is testing

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Who this might be right for
Unresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer
AstraZeneca 1,246
Testing effectiveness (Phase 2)WithdrawnNCT03935347
What this trial is testing

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma+3 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT03397394
What this trial is testing

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaMetastatic Urothelial Carcinoma+5 more
pharmaand GmbH 97
Testing effectiveness (Phase 2)WithdrawnNCT01639521
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Who this might be right for
Anterior Urethral CancerLocalized Transitional Cell Cancer of the Renal Pelvis and UreterPosterior Urethral Cancer+7 more
University of Southern California
Testing effectiveness (Phase 2)Study completedNCT03513952
What this trial is testing

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Who this might be right for
Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT03237780
What this trial is testing

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 72
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Testing effectiveness (Phase 2)Study completedNCT01326871
What this trial is testing

ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma of BladderUrethra CancerUreter Cancer+1 more
Altor BioScience 68
Testing effectiveness (Phase 2)Study completedNCT00112671
What this trial is testing

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Who this might be right for
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter+4 more
National Cancer Institute (NCI) 17
Testing effectiveness (Phase 2)Study completedNCT03617913
What this trial is testing

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8+9 more
Mayo Clinic 2
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Ended earlyNCT00022633
What this trial is testing

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 65
Testing effectiveness (Phase 2)UnknownNCT00005958
What this trial is testing

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Amgen
Not applicableLooking for participantsNCT01050504
What this trial is testing

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Who this might be right for
Localized Renal Pelvis and Ureter Urothelial CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the Bone+8 more
University of Washington 1,500
Testing effectiveness (Phase 2)Looking for participantsNCT06823427
What this trial is testing

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent+1 more
Mabwell (Shanghai) Bioscience Co., Ltd. 60
Early research (Phase 1)Study completedNCT00623064
What this trial is testing

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
European Organisation for Research and Treatment of Cancer - EORTC 18
Early research (Phase 1)Looking for participantsNCT05614739
What this trial is testing

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company 677
Next Page